ImmuCell Corp Files 8-K: Material Agreement & Financial Obligations

TL;DR

ImmuCell signed a big deal and took on new debt. Watch this space.

AI Summary

On August 7, 2025, ImmuCell Corporation entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The filing includes financial statements and exhibits.

Why It Matters

This 8-K filing signals a significant new agreement and potential financial commitments for ImmuCell Corporation, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement and new financial obligations, which inherently carry financial risks that need further investigation.

Key Players & Entities

• ImmuCell Corporation (company) — Registrant
• August 07, 2025 (date) — Date of earliest event reported
• DE (jurisdiction) — State of incorporation
• 001-12934 (commission_file_number) — SEC File Number
• 01-0382980 (ein) — IRS Employer Identification No.
• 56 Evergreen Drive (address) — Principal executive offices
• Portland (city) — Principal executive offices
• Maine (state) — Principal executive offices
• 04103 (zip_code) — Principal executive offices
• 207 - 878-2770 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The NASDAQ
• $2,327,119 — transaction in the principal amount of $2,327,119, and bearing interest at a fixed rate o
• $1,525,852 — from MCB with an outstanding balance of $1,525,852 that was bearing interest at a fixed ra
• $768,209 — e (FAME) with an outstanding balance of $768,209 that was bearing interest at a fixed ra

Filing Documents

• ea0252890-8k_immucell.htm (8-K) — 29KB
• ea025289001ex10-1_immucell.htm (EX-10.1) — 187KB
• ea025289001ex10-2_immucell.htm (EX-10.2) — 37KB
• ea025289001ex99-1_immucell.htm (EX-99.1) — 15KB
• ex10-1_001.jpg (GRAPHIC) — 24KB
• ex10-2_001.jpg (GRAPHIC) — 23KB
• 0001213900-25-074983.txt ( ) — 556KB
• iccc-20250807.xsd (EX-101.SCH) — 3KB
• iccc-20250807_lab.xml (EX-101.LAB) — 33KB
• iccc-20250807_pre.xml (EX-101.PRE) — 22KB
• ea0252890-8k_immucell_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement

03 Creation of a Direct Financial Obligation or an Obligation

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant On August 7, 2025, ImmuCell Corporation (the "Company") entered into a Loan Agreement, Promissory Note, and other definitive agreements covering a loan transaction with Maine Community Bank (MCB). Proceeds from such loan transaction in the principal amount of $2,327,119, and bearing interest at a fixed rate of 6.5% per annum, were used to pay off a loan from MCB with an outstanding balance of $1,525,852 that was bearing interest at a fixed rate of 7% per annum and a loan from the Finance Authority of Maine (FAME) with an outstanding balance of $768,209 that was bearing interest at a fixed rate of 8% per annum. The loan is secured by a security interest with respect to substantially all of the Company's assets. The Company's failure to make timely payments of principal and interest, or otherwise comply with the terms of its agreements with MCB, would entitle MCB to accelerate the maturity of such debt and demand repayment in full. The foregoing descriptions of the Loan Agreement and the Promissory Note are qualified in their entirety by reference to the Loan Agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference, and to the Promissory Note, which is filed as Exhibit 10.2 hereto and incorporated herein by reference.

01. Exhibits

Item 9.01. Exhibits. (d) Exhibits . 10.1 Loan Agreement between the Company and Maine Community Bank dated as of August 7, 2025. 10.2 Promissory Note executed by the Company in favor of Maine Community Bank dated as of August 7, 2025. 99.1 Press Release of the Company dated August 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: August 12, 2025 By: /s/ Michael F. Brigham Michael F. Brigham President and Chief Executive Officer Date: August 12, 2025 By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer 2 Exhibit Index Exhibit No. Description 10.1 Loan Agreement between the Company and Maine Community Bank dated as of August 7, 2025. 10.2 Promissory Note executed by the Company in favor of Maine Community Bank dated as of August 7, 2025. 99.1 Press Release of the Company dated August 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

View Full Filing

View this 8-K filing on SEC EDGAR